• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » David Ho

David Ho

Articles

ARTICLES

Panelists talk tech tools, other trends at Phar-East meeting

March 27, 2019
By David Ho

In today's drug development environment, companies should seek 'niche-busters'

March 27, 2019
By David Ho
SINGAPORE – The days of blockbuster drugs may be coming to an end, but Harish Dave, chief medical officer at Singapore-based Aum Biosciences Pte. Ltd., offered companies a new term. During the second day of the Phar-East Pharma and Biotech Festival biopharma conference, Dave said companies should focus on "niche-busters" and finding new sectors to dominate instead.
Read More

VC investors: Asia's biopharma, med-tech ecosystem is maturing

March 27, 2019
By David Ho
SINGAPORE – Several talks and forums at the recent Phar-East Pharma and Biotech Festival focused on funding and its relation to the ecosystem in Asia. Naturally, much of this discussion centered on Singapore, the host country for the event and the most developed biotech and med-tech hub in Southeast Asia. Tong Hsien-Hui, head of venture investing at SGInnovate, said it makes sense for Singapore, given its size, to build its ecosystem to focus on niches.
Read More

Takeda and Legochem take ADC partnership to next step

March 27, 2019
By David Ho
HONG KONG – Legochem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a research collaboration and license agreement to develop antibody-drug conjugates (ADCs) in immuno-oncology, a follow-up to their deal in 2017 to evaluate the potential of next-generation ADC candidates based on Legochem's ADC linker and conjugation technology platform, Conjuall. (See BioWorld, Jan. 25, 2017.)
Read More

Takeda, Legochem take ADC partnership to next step

March 27, 2019
By David Ho
HONG KONG – Legochem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a research collaboration and license agreement to develop antibody-drug conjugates (ADCs) in immuno-oncology, a follow-up to their deal in 2017 to evaluate the potential of next-generation ADC candidates based on Legochem's ADC linker and conjugation technology platform, Conjuall. 
Read More

VC investors: Asia's biopharma, med-tech ecosystem is maturing

March 22, 2019
By David Ho
SINGAPORE – Several talks and forums at the recent Phar-East Pharma and Biotech Festival focused on funding and its relation to the ecosystem in Asia. Naturally, much of this discussion centered on Singapore, the host country for the event and the most developed biotech and med-tech hub in Southeast Asia. Tong Hsien-Hui, head of venture investing at SGInnovate, said it makes sense for Singapore, given its size, to build its ecosystem to focus on niches.
Read More

In today's drug development environment, companies should seek 'niche-busters'

March 21, 2019
By David Ho
SINGAPORE – The days of blockbuster drugs may be coming to an end, but Harish Dave, chief medical officer at Singapore-based Aum Biosciences Pte. Ltd., offered companies a new term. During the second day of the Phar-East Pharma and Biotech Festival biopharma conference, Dave said companies should focus on "niche-busters" and finding new sectors to dominate instead.
Read More

Regen med, biosimilars can drive more Asian innovation

March 20, 2019
By David Ho
SINGAPORE – For David Lane, chief scientist at the Agency for Science, Technology and Research (A*STAR), it is clear what is required for driving innovation in Asia.
Read More

Regen med, biosimilars can drive more Asian innovation

March 20, 2019
By David Ho
SINGAPORE – For David Lane, chief scientist at the Agency for Science, Technology and Research (A*STAR), it is clear what is required for driving innovation in Asia. "You need to sustain basic science," Lane said in his opening keynote speech at the Phar-East Pharma and Biotech Festival on Tuesday. "People want instant results, but sustaining basic science is the key to innovation."
Read More

BGN's AI platform for ALS progression holds key to improving care and treatment

Feb. 28, 2019
By David Ho
View All Articles by David Ho

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 29, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe